Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Supply, Demand and Key Producers, 2026-2032
The global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market size is expected to reach $ 1025 million by 2032, rising at a market growth of 7.7% CAGR during the forecast period (2026-2032).
Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs refer to a class of medications used to treat Paroxysmal Nocturnal Hemoglobinuria, a rare, life-threatening blood disorder characterized by the destruction of red blood cells, blood clots, and impaired bone marrow function. These drugs primarily work by inhibiting the complement system, an immune response that, when overactive in PNH patients, leads to the destruction of red blood cells. Treatments like eculizumab and ravulizumab are commonly used PNH drugs, helping to reduce hemolysis (red blood cell breakdown), manage symptoms, and improve patients' quality of life.
CANbridge Pharmaceuticals Inc., Kira Pharmaceuticals, Wuhan Createrna Science and Technology Co., Ltd., NovelMed, Akari Therapeutics, Omeros Corporation and Regeneron Pharmaceuticals are mainly developing complement-targeted drugs and clinical-stage candidate drugs for PNH. None of them have launched commercially available finished PNH drugs so far. Therefore, these enterprises are listed as PNH drug pipeline players and potential market entrants in this report, and shall not be combined with manufacturers of marketed PNH drugs for statistics on current commercial sales volume.
In 2025, global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs production reached approximately 98 K doses, with an average global market price of around US$ 6,100 per dose.
The Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs market is experiencing significant growth, driven by the rising prevalence of the disease and increasing awareness. The market size is expanding, with North America, particularly the U.S., and Europe being the major sales regions due to advanced healthcare infrastructure and higher diagnosis rates. Emerging markets in Asia-Pacific present significant opportunities due to a growing healthcare sector and rising patient awareness. However, challenges such as high treatment costs and limited access to advanced therapies in developing regions persist. Future product development trends focus on improving efficacy, reducing treatment frequency, and introducing cost-effective biosimilars, potentially expanding access to underserved populations.
This report studies the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs total production and demand, 2021-2032, (K Doses)
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs total production value, 2021-2032, (USD Million)
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Doses), (based on production site)
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs consumption by region & country, CAGR, 2021-2032 & (K Doses)
U.S. VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs domestic production, consumption, key domestic manufacturers and share
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Doses)
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Doses)
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Doses)
This report profiles key players in the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Novartis, Apellis Pharmaceuticals, Roche, Amgen, Chugai Pharmaceutical, Sobi, Samsung Bioepis, Teva Pharmaceutical Industries, CANbridge Pharmaceuticals Inc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Doses) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market, By Region:
1. How big is the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market?
2. What is the demand of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market?
3. What is the year over year growth of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market?
4. What is the production and production value of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market?
5. Who are the key producers in the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market?
6. What are the growth factors driving the market demand?
Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs refer to a class of medications used to treat Paroxysmal Nocturnal Hemoglobinuria, a rare, life-threatening blood disorder characterized by the destruction of red blood cells, blood clots, and impaired bone marrow function. These drugs primarily work by inhibiting the complement system, an immune response that, when overactive in PNH patients, leads to the destruction of red blood cells. Treatments like eculizumab and ravulizumab are commonly used PNH drugs, helping to reduce hemolysis (red blood cell breakdown), manage symptoms, and improve patients' quality of life.
CANbridge Pharmaceuticals Inc., Kira Pharmaceuticals, Wuhan Createrna Science and Technology Co., Ltd., NovelMed, Akari Therapeutics, Omeros Corporation and Regeneron Pharmaceuticals are mainly developing complement-targeted drugs and clinical-stage candidate drugs for PNH. None of them have launched commercially available finished PNH drugs so far. Therefore, these enterprises are listed as PNH drug pipeline players and potential market entrants in this report, and shall not be combined with manufacturers of marketed PNH drugs for statistics on current commercial sales volume.
In 2025, global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs production reached approximately 98 K doses, with an average global market price of around US$ 6,100 per dose.
The Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs market is experiencing significant growth, driven by the rising prevalence of the disease and increasing awareness. The market size is expanding, with North America, particularly the U.S., and Europe being the major sales regions due to advanced healthcare infrastructure and higher diagnosis rates. Emerging markets in Asia-Pacific present significant opportunities due to a growing healthcare sector and rising patient awareness. However, challenges such as high treatment costs and limited access to advanced therapies in developing regions persist. Future product development trends focus on improving efficacy, reducing treatment frequency, and introducing cost-effective biosimilars, potentially expanding access to underserved populations.
This report studies the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs total production and demand, 2021-2032, (K Doses)
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs total production value, 2021-2032, (USD Million)
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Doses), (based on production site)
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs consumption by region & country, CAGR, 2021-2032 & (K Doses)
U.S. VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs domestic production, consumption, key domestic manufacturers and share
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Doses)
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Doses)
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Doses)
This report profiles key players in the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Novartis, Apellis Pharmaceuticals, Roche, Amgen, Chugai Pharmaceutical, Sobi, Samsung Bioepis, Teva Pharmaceutical Industries, CANbridge Pharmaceuticals Inc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Doses) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Oral Drugs
- Injectable Drugs
- C5 Inhibitors
- C3 Inhibitors
- Other
- Short-Acting: < 2 Weeks
- Medium-Acting: 2?8 Weeks
- Long-Acting: > 8 Weeks
- Pharmaceutical and Biotechnology Companies
- Clinical
- Others
- AstraZeneca
- Novartis
- Apellis Pharmaceuticals
- Roche
- Amgen
- Chugai Pharmaceutical
- Sobi
- Samsung Bioepis
- Teva Pharmaceutical Industries
- CANbridge Pharmaceuticals Inc.
- Kira Pharmaceuticals
- Wuhan Createrna Science and Technology Co., Ltd.
- NovelMed
- Akari Therapeutics
- Omeros Corporation
- Regeneron Pharmaceuticals
1. How big is the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market?
2. What is the demand of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market?
3. What is the year over year growth of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market?
4. What is the production and production value of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market?
5. Who are the key producers in the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Introduction
1.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Supply & Forecast
1.2.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value (2021 & 2025 & 2032)
1.2.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032)
1.2.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Pricing Trends (2021-2032)
1.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Region (Based on Production Site)
1.3.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Region (2021-2032)
1.3.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Region (2021-2032)
1.3.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Region (2021-2032)
1.3.4 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032)
1.3.5 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032)
1.3.6 China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032)
1.3.7 Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Major Market Trends
2 DEMAND SUMMARY
2.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Demand (2021-2032)
2.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption by Region
2.2.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption by Region (2021-2026)
2.2.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Forecast by Region (2027-2032)
2.3 United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032)
2.4 China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032)
2.5 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032)
2.6 Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032)
2.7 South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032)
2.8 ASEAN Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032)
2.9 India Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Manufacturer (2021-2026)
3.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Manufacturer (2021-2026)
3.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Manufacturer (2021-2026)
3.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs in 2025
3.5.3 Global Concentration Ratios (CR8) for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs in 2025
3.6 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Overall Company Footprint Analysis
3.6.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Region Footprint
3.6.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Company Product Type Footprint
3.6.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Comparison
4.1.1 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Comparison
4.2.1 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Comparison
4.3.1 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value (2021-2026)
4.4.3 United States Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2026)
4.5 China Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers and Market Share
4.5.1 China Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value (2021-2026)
4.5.3 China Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2026)
4.6 Rest of World Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Oral Drugs
5.2.2 Injectable Drugs
5.3 Market Segment by Type
5.3.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Type (2021-2032)
5.3.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Type (2021-2032)
5.3.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY COMPLEMENT TARGET
6.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size Overview by Complement Target: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Complement Target
6.2.1 C5 Inhibitors
6.2.2 C3 Inhibitors
6.2.3 Other
6.3 Market Segment by Complement Target
6.3.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Complement Target (2021-2032)
6.3.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Complement Target (2021-2032)
6.3.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Complement Target (2021-2032)
7 MARKET ANALYSIS BY DURATION OF ACTION
7.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size Overview by Duration of Action: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Duration of Action
7.2.1 Short-Acting: < 2 Weeks
7.2.2 Medium-Acting: 2?8 Weeks
7.2.3 Long-Acting: > 8 Weeks
7.3 Market Segment by Duration of Action
7.3.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Duration of Action (2021-2032)
7.3.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Duration of Action (2021-2032)
7.3.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Duration of Action (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Pharmaceutical and Biotechnology Companies
8.2.2 Clinical
8.2.3 Others
8.3 Market Segment by Application
8.3.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Application (2021-2032)
8.3.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Application (2021-2032)
8.3.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 AstraZeneca
9.1.1 AstraZeneca Details
9.1.2 AstraZeneca Major Business
9.1.3 AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.1.4 AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 AstraZeneca Recent Developments/Updates
9.1.6 AstraZeneca Competitive Strengths & Weaknesses
9.2 Novartis
9.2.1 Novartis Details
9.2.2 Novartis Major Business
9.2.3 Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.2.4 Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Novartis Recent Developments/Updates
9.2.6 Novartis Competitive Strengths & Weaknesses
9.3 Apellis Pharmaceuticals
9.3.1 Apellis Pharmaceuticals Details
9.3.2 Apellis Pharmaceuticals Major Business
9.3.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.3.4 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Apellis Pharmaceuticals Recent Developments/Updates
9.3.6 Apellis Pharmaceuticals Competitive Strengths & Weaknesses
9.4 Roche
9.4.1 Roche Details
9.4.2 Roche Major Business
9.4.3 Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.4.4 Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Roche Recent Developments/Updates
9.4.6 Roche Competitive Strengths & Weaknesses
9.5 Amgen
9.5.1 Amgen Details
9.5.2 Amgen Major Business
9.5.3 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.5.4 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Amgen Recent Developments/Updates
9.5.6 Amgen Competitive Strengths & Weaknesses
9.6 Chugai Pharmaceutical
9.6.1 Chugai Pharmaceutical Details
9.6.2 Chugai Pharmaceutical Major Business
9.6.3 Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.6.4 Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Chugai Pharmaceutical Recent Developments/Updates
9.6.6 Chugai Pharmaceutical Competitive Strengths & Weaknesses
9.7 Sobi
9.7.1 Sobi Details
9.7.2 Sobi Major Business
9.7.3 Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.7.4 Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Sobi Recent Developments/Updates
9.7.6 Sobi Competitive Strengths & Weaknesses
9.8 Samsung Bioepis
9.8.1 Samsung Bioepis Details
9.8.2 Samsung Bioepis Major Business
9.8.3 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.8.4 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Samsung Bioepis Recent Developments/Updates
9.8.6 Samsung Bioepis Competitive Strengths & Weaknesses
9.9 Teva Pharmaceutical Industries
9.9.1 Teva Pharmaceutical Industries Details
9.9.2 Teva Pharmaceutical Industries Major Business
9.9.3 Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.9.4 Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Teva Pharmaceutical Industries Recent Developments/Updates
9.9.6 Teva Pharmaceutical Industries Competitive Strengths & Weaknesses
9.10 CANbridge Pharmaceuticals Inc.
9.10.1 CANbridge Pharmaceuticals Inc. Details
9.10.2 CANbridge Pharmaceuticals Inc. Major Business
9.10.3 CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.10.4 CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 CANbridge Pharmaceuticals Inc. Recent Developments/Updates
9.10.6 CANbridge Pharmaceuticals Inc. Competitive Strengths & Weaknesses
9.11 Kira Pharmaceuticals
9.11.1 Kira Pharmaceuticals Details
9.11.2 Kira Pharmaceuticals Major Business
9.11.3 Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.11.4 Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Kira Pharmaceuticals Recent Developments/Updates
9.11.6 Kira Pharmaceuticals Competitive Strengths & Weaknesses
9.12 Wuhan Createrna Science and Technology Co., Ltd.
9.12.1 Wuhan Createrna Science and Technology Co., Ltd. Details
9.12.2 Wuhan Createrna Science and Technology Co., Ltd. Major Business
9.12.3 Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.12.4 Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Wuhan Createrna Science and Technology Co., Ltd. Recent Developments/Updates
9.12.6 Wuhan Createrna Science and Technology Co., Ltd. Competitive Strengths & Weaknesses
9.13 NovelMed
9.13.1 NovelMed Details
9.13.2 NovelMed Major Business
9.13.3 NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.13.4 NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 NovelMed Recent Developments/Updates
9.13.6 NovelMed Competitive Strengths & Weaknesses
9.14 Akari Therapeutics
9.14.1 Akari Therapeutics Details
9.14.2 Akari Therapeutics Major Business
9.14.3 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.14.4 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Akari Therapeutics Recent Developments/Updates
9.14.6 Akari Therapeutics Competitive Strengths & Weaknesses
9.15 Omeros Corporation
9.15.1 Omeros Corporation Details
9.15.2 Omeros Corporation Major Business
9.15.3 Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.15.4 Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 Omeros Corporation Recent Developments/Updates
9.15.6 Omeros Corporation Competitive Strengths & Weaknesses
9.16 Regeneron Pharmaceuticals
9.16.1 Regeneron Pharmaceuticals Details
9.16.2 Regeneron Pharmaceuticals Major Business
9.16.3 Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.16.4 Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.16.5 Regeneron Pharmaceuticals Recent Developments/Updates
9.16.6 Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Chain
10.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Upstream Analysis
10.2.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Core Raw Materials
10.2.2 Main Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Mode
10.6 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Procurement Model
10.7 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Sales Model and Sales Channels
10.7.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Model
10.7.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Introduction
1.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Supply & Forecast
1.2.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value (2021 & 2025 & 2032)
1.2.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032)
1.2.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Pricing Trends (2021-2032)
1.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Region (Based on Production Site)
1.3.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Region (2021-2032)
1.3.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Region (2021-2032)
1.3.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Region (2021-2032)
1.3.4 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032)
1.3.5 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032)
1.3.6 China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032)
1.3.7 Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Major Market Trends
2 DEMAND SUMMARY
2.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Demand (2021-2032)
2.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption by Region
2.2.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption by Region (2021-2026)
2.2.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Forecast by Region (2027-2032)
2.3 United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032)
2.4 China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032)
2.5 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032)
2.6 Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032)
2.7 South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032)
2.8 ASEAN Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032)
2.9 India Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Manufacturer (2021-2026)
3.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Manufacturer (2021-2026)
3.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Manufacturer (2021-2026)
3.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs in 2025
3.5.3 Global Concentration Ratios (CR8) for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs in 2025
3.6 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Overall Company Footprint Analysis
3.6.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Region Footprint
3.6.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Company Product Type Footprint
3.6.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Comparison
4.1.1 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Comparison
4.2.1 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Comparison
4.3.1 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value (2021-2026)
4.4.3 United States Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2026)
4.5 China Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers and Market Share
4.5.1 China Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value (2021-2026)
4.5.3 China Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2026)
4.6 Rest of World Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Oral Drugs
5.2.2 Injectable Drugs
5.3 Market Segment by Type
5.3.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Type (2021-2032)
5.3.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Type (2021-2032)
5.3.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY COMPLEMENT TARGET
6.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size Overview by Complement Target: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Complement Target
6.2.1 C5 Inhibitors
6.2.2 C3 Inhibitors
6.2.3 Other
6.3 Market Segment by Complement Target
6.3.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Complement Target (2021-2032)
6.3.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Complement Target (2021-2032)
6.3.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Complement Target (2021-2032)
7 MARKET ANALYSIS BY DURATION OF ACTION
7.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size Overview by Duration of Action: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Duration of Action
7.2.1 Short-Acting: < 2 Weeks
7.2.2 Medium-Acting: 2?8 Weeks
7.2.3 Long-Acting: > 8 Weeks
7.3 Market Segment by Duration of Action
7.3.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Duration of Action (2021-2032)
7.3.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Duration of Action (2021-2032)
7.3.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Duration of Action (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Pharmaceutical and Biotechnology Companies
8.2.2 Clinical
8.2.3 Others
8.3 Market Segment by Application
8.3.1 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Application (2021-2032)
8.3.2 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Application (2021-2032)
8.3.3 World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 AstraZeneca
9.1.1 AstraZeneca Details
9.1.2 AstraZeneca Major Business
9.1.3 AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.1.4 AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 AstraZeneca Recent Developments/Updates
9.1.6 AstraZeneca Competitive Strengths & Weaknesses
9.2 Novartis
9.2.1 Novartis Details
9.2.2 Novartis Major Business
9.2.3 Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.2.4 Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Novartis Recent Developments/Updates
9.2.6 Novartis Competitive Strengths & Weaknesses
9.3 Apellis Pharmaceuticals
9.3.1 Apellis Pharmaceuticals Details
9.3.2 Apellis Pharmaceuticals Major Business
9.3.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.3.4 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Apellis Pharmaceuticals Recent Developments/Updates
9.3.6 Apellis Pharmaceuticals Competitive Strengths & Weaknesses
9.4 Roche
9.4.1 Roche Details
9.4.2 Roche Major Business
9.4.3 Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.4.4 Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Roche Recent Developments/Updates
9.4.6 Roche Competitive Strengths & Weaknesses
9.5 Amgen
9.5.1 Amgen Details
9.5.2 Amgen Major Business
9.5.3 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.5.4 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Amgen Recent Developments/Updates
9.5.6 Amgen Competitive Strengths & Weaknesses
9.6 Chugai Pharmaceutical
9.6.1 Chugai Pharmaceutical Details
9.6.2 Chugai Pharmaceutical Major Business
9.6.3 Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.6.4 Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Chugai Pharmaceutical Recent Developments/Updates
9.6.6 Chugai Pharmaceutical Competitive Strengths & Weaknesses
9.7 Sobi
9.7.1 Sobi Details
9.7.2 Sobi Major Business
9.7.3 Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.7.4 Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Sobi Recent Developments/Updates
9.7.6 Sobi Competitive Strengths & Weaknesses
9.8 Samsung Bioepis
9.8.1 Samsung Bioepis Details
9.8.2 Samsung Bioepis Major Business
9.8.3 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.8.4 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Samsung Bioepis Recent Developments/Updates
9.8.6 Samsung Bioepis Competitive Strengths & Weaknesses
9.9 Teva Pharmaceutical Industries
9.9.1 Teva Pharmaceutical Industries Details
9.9.2 Teva Pharmaceutical Industries Major Business
9.9.3 Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.9.4 Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Teva Pharmaceutical Industries Recent Developments/Updates
9.9.6 Teva Pharmaceutical Industries Competitive Strengths & Weaknesses
9.10 CANbridge Pharmaceuticals Inc.
9.10.1 CANbridge Pharmaceuticals Inc. Details
9.10.2 CANbridge Pharmaceuticals Inc. Major Business
9.10.3 CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.10.4 CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 CANbridge Pharmaceuticals Inc. Recent Developments/Updates
9.10.6 CANbridge Pharmaceuticals Inc. Competitive Strengths & Weaknesses
9.11 Kira Pharmaceuticals
9.11.1 Kira Pharmaceuticals Details
9.11.2 Kira Pharmaceuticals Major Business
9.11.3 Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.11.4 Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Kira Pharmaceuticals Recent Developments/Updates
9.11.6 Kira Pharmaceuticals Competitive Strengths & Weaknesses
9.12 Wuhan Createrna Science and Technology Co., Ltd.
9.12.1 Wuhan Createrna Science and Technology Co., Ltd. Details
9.12.2 Wuhan Createrna Science and Technology Co., Ltd. Major Business
9.12.3 Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.12.4 Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Wuhan Createrna Science and Technology Co., Ltd. Recent Developments/Updates
9.12.6 Wuhan Createrna Science and Technology Co., Ltd. Competitive Strengths & Weaknesses
9.13 NovelMed
9.13.1 NovelMed Details
9.13.2 NovelMed Major Business
9.13.3 NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.13.4 NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 NovelMed Recent Developments/Updates
9.13.6 NovelMed Competitive Strengths & Weaknesses
9.14 Akari Therapeutics
9.14.1 Akari Therapeutics Details
9.14.2 Akari Therapeutics Major Business
9.14.3 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.14.4 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Akari Therapeutics Recent Developments/Updates
9.14.6 Akari Therapeutics Competitive Strengths & Weaknesses
9.15 Omeros Corporation
9.15.1 Omeros Corporation Details
9.15.2 Omeros Corporation Major Business
9.15.3 Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.15.4 Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 Omeros Corporation Recent Developments/Updates
9.15.6 Omeros Corporation Competitive Strengths & Weaknesses
9.16 Regeneron Pharmaceuticals
9.16.1 Regeneron Pharmaceuticals Details
9.16.2 Regeneron Pharmaceuticals Major Business
9.16.3 Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
9.16.4 Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.16.5 Regeneron Pharmaceuticals Recent Developments/Updates
9.16.6 Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Chain
10.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Upstream Analysis
10.2.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Core Raw Materials
10.2.2 Main Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Mode
10.6 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Procurement Model
10.7 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Sales Model and Sales Channels
10.7.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Model
10.7.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Region (2021-2026) & (USD Million)
Table 3. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Region (2027-2032) & (USD Million)
Table 4. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Region (2021-2026)
Table 5. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Region (2027-2032)
Table 6. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Region (2021-2026) & (K Doses)
Table 7. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Region (2027-2032) & (K Doses)
Table 8. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share by Region (2021-2026)
Table 9. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share by Region (2027-2032)
Table 10. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Major Market Trends
Table 13. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Doses)
Table 14. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption by Region (2021-2026) & (K Doses)
Table 15. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Forecast by Region (2027-2032) & (K Doses)
Table 16. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Producers in 2025
Table 18. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Manufacturer (2021-2026) & (K Doses)
Table 19. Production Market Share of Key Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Producers in 2025
Table 20. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Company Evaluation Quadrant
Table 22. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Site of Key Manufacturer
Table 24. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Company Product Type Footprint
Table 25. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Company Product Application Footprint
Table 26. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Competitive Factors
Table 27. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs New Entrant and Capacity Expansion Plans
Table 28. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Mergers & Acquisitions Activity
Table 29. United States VS China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Comparison, (2021 & 2025 & 2032) & (K Doses)
Table 31. United States VS China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Comparison, (2021 & 2025 & 2032) & (K Doses)
Table 32. United States Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2026) & (K Doses)
Table 36. United States Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share (2021-2026)
Table 37. China Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, (2021-2026) & (K Doses)
Table 41. China Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share (2021-2026)
Table 42. Rest of World Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, (2021-2026) & (K Doses)
Table 46. Rest of World Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share (2021-2026)
Table 47. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Type (2021-2026) & (K Doses)
Table 49. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Type (2027-2032) & (K Doses)
Table 50. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Type (2021-2026) & (USD Million)
Table 51. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Type (2027-2032) & (USD Million)
Table 52. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Complement Target, (USD Million), 2021 & 2025 & 2032
Table 55. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Complement Target (2021-2026) & (K Doses)
Table 56. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Complement Target (2027-2032) & (K Doses)
Table 57. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Complement Target (2021-2026) & (USD Million)
Table 58. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Complement Target (2027-2032) & (USD Million)
Table 59. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Complement Target (2021-2026) & (US$/Dose)
Table 60. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Complement Target (2027-2032) & (US$/Dose)
Table 61. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Duration of Action, (USD Million), 2021 & 2025 & 2032
Table 62. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Duration of Action (2021-2026) & (K Doses)
Table 63. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Duration of Action (2027-2032) & (K Doses)
Table 64. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Duration of Action (2021-2026) & (USD Million)
Table 65. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Duration of Action (2027-2032) & (USD Million)
Table 66. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Duration of Action (2021-2026) & (US$/Dose)
Table 67. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Duration of Action (2027-2032) & (US$/Dose)
Table 68. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Application (2021-2026) & (K Doses)
Table 70. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Application (2027-2032) & (K Doses)
Table 71. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Application (2021-2026) & (USD Million)
Table 72. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Application (2027-2032) & (USD Million)
Table 73. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Application (2027-2032) & (US$/Dose)
Table 75. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 76. AstraZeneca Major Business
Table 77. AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 78. AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. AstraZeneca Recent Developments/Updates
Table 80. AstraZeneca Competitive Strengths & Weaknesses
Table 81. Novartis Basic Information, Manufacturing Base and Competitors
Table 82. Novartis Major Business
Table 83. Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 84. Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Novartis Recent Developments/Updates
Table 86. Novartis Competitive Strengths & Weaknesses
Table 87. Apellis Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 88. Apellis Pharmaceuticals Major Business
Table 89. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 90. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Apellis Pharmaceuticals Recent Developments/Updates
Table 92. Apellis Pharmaceuticals Competitive Strengths & Weaknesses
Table 93. Roche Basic Information, Manufacturing Base and Competitors
Table 94. Roche Major Business
Table 95. Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 96. Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Roche Recent Developments/Updates
Table 98. Roche Competitive Strengths & Weaknesses
Table 99. Amgen Basic Information, Manufacturing Base and Competitors
Table 100. Amgen Major Business
Table 101. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 102. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Amgen Recent Developments/Updates
Table 104. Amgen Competitive Strengths & Weaknesses
Table 105. Chugai Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 106. Chugai Pharmaceutical Major Business
Table 107. Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 108. Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Chugai Pharmaceutical Recent Developments/Updates
Table 110. Chugai Pharmaceutical Competitive Strengths & Weaknesses
Table 111. Sobi Basic Information, Manufacturing Base and Competitors
Table 112. Sobi Major Business
Table 113. Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 114. Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Sobi Recent Developments/Updates
Table 116. Sobi Competitive Strengths & Weaknesses
Table 117. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 118. Samsung Bioepis Major Business
Table 119. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 120. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Samsung Bioepis Recent Developments/Updates
Table 122. Samsung Bioepis Competitive Strengths & Weaknesses
Table 123. Teva Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 124. Teva Pharmaceutical Industries Major Business
Table 125. Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 126. Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Teva Pharmaceutical Industries Recent Developments/Updates
Table 128. Teva Pharmaceutical Industries Competitive Strengths & Weaknesses
Table 129. CANbridge Pharmaceuticals Inc. Basic Information, Manufacturing Base and Competitors
Table 130. CANbridge Pharmaceuticals Inc. Major Business
Table 131. CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 132. CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. CANbridge Pharmaceuticals Inc. Recent Developments/Updates
Table 134. CANbridge Pharmaceuticals Inc. Competitive Strengths & Weaknesses
Table 135. Kira Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 136. Kira Pharmaceuticals Major Business
Table 137. Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 138. Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Kira Pharmaceuticals Recent Developments/Updates
Table 140. Kira Pharmaceuticals Competitive Strengths & Weaknesses
Table 141. Wuhan Createrna Science and Technology Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 142. Wuhan Createrna Science and Technology Co., Ltd. Major Business
Table 143. Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 144. Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Wuhan Createrna Science and Technology Co., Ltd. Recent Developments/Updates
Table 146. Wuhan Createrna Science and Technology Co., Ltd. Competitive Strengths & Weaknesses
Table 147. NovelMed Basic Information, Manufacturing Base and Competitors
Table 148. NovelMed Major Business
Table 149. NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 150. NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. NovelMed Recent Developments/Updates
Table 152. NovelMed Competitive Strengths & Weaknesses
Table 153. Akari Therapeutics Basic Information, Manufacturing Base and Competitors
Table 154. Akari Therapeutics Major Business
Table 155. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 156. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Akari Therapeutics Recent Developments/Updates
Table 158. Akari Therapeutics Competitive Strengths & Weaknesses
Table 159. Omeros Corporation Basic Information, Manufacturing Base and Competitors
Table 160. Omeros Corporation Major Business
Table 161. Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 162. Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 163. Omeros Corporation Recent Developments/Updates
Table 164. Omeros Corporation Competitive Strengths & Weaknesses
Table 165. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 166. Regeneron Pharmaceuticals Major Business
Table 167. Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 168. Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 169. Regeneron Pharmaceuticals Recent Developments/Updates
Table 170. Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
Table 171. Global Key Players of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Upstream (Raw Materials)
Table 172. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Typical Customers
Table 173. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Typical Distributors
Table 1. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Region (2021-2026) & (USD Million)
Table 3. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Region (2027-2032) & (USD Million)
Table 4. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Region (2021-2026)
Table 5. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Region (2027-2032)
Table 6. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Region (2021-2026) & (K Doses)
Table 7. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Region (2027-2032) & (K Doses)
Table 8. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share by Region (2021-2026)
Table 9. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share by Region (2027-2032)
Table 10. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Major Market Trends
Table 13. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Doses)
Table 14. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption by Region (2021-2026) & (K Doses)
Table 15. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Forecast by Region (2027-2032) & (K Doses)
Table 16. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Producers in 2025
Table 18. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Manufacturer (2021-2026) & (K Doses)
Table 19. Production Market Share of Key Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Producers in 2025
Table 20. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Company Evaluation Quadrant
Table 22. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Site of Key Manufacturer
Table 24. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Company Product Type Footprint
Table 25. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Company Product Application Footprint
Table 26. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Competitive Factors
Table 27. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs New Entrant and Capacity Expansion Plans
Table 28. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Mergers & Acquisitions Activity
Table 29. United States VS China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Comparison, (2021 & 2025 & 2032) & (K Doses)
Table 31. United States VS China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Comparison, (2021 & 2025 & 2032) & (K Doses)
Table 32. United States Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2026) & (K Doses)
Table 36. United States Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share (2021-2026)
Table 37. China Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, (2021-2026) & (K Doses)
Table 41. China Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share (2021-2026)
Table 42. Rest of World Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production, (2021-2026) & (K Doses)
Table 46. Rest of World Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share (2021-2026)
Table 47. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Type (2021-2026) & (K Doses)
Table 49. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Type (2027-2032) & (K Doses)
Table 50. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Type (2021-2026) & (USD Million)
Table 51. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Type (2027-2032) & (USD Million)
Table 52. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Complement Target, (USD Million), 2021 & 2025 & 2032
Table 55. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Complement Target (2021-2026) & (K Doses)
Table 56. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Complement Target (2027-2032) & (K Doses)
Table 57. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Complement Target (2021-2026) & (USD Million)
Table 58. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Complement Target (2027-2032) & (USD Million)
Table 59. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Complement Target (2021-2026) & (US$/Dose)
Table 60. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Complement Target (2027-2032) & (US$/Dose)
Table 61. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Duration of Action, (USD Million), 2021 & 2025 & 2032
Table 62. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Duration of Action (2021-2026) & (K Doses)
Table 63. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Duration of Action (2027-2032) & (K Doses)
Table 64. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Duration of Action (2021-2026) & (USD Million)
Table 65. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Duration of Action (2027-2032) & (USD Million)
Table 66. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Duration of Action (2021-2026) & (US$/Dose)
Table 67. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Duration of Action (2027-2032) & (US$/Dose)
Table 68. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Application (2021-2026) & (K Doses)
Table 70. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production by Application (2027-2032) & (K Doses)
Table 71. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Application (2021-2026) & (USD Million)
Table 72. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Application (2027-2032) & (USD Million)
Table 73. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Application (2027-2032) & (US$/Dose)
Table 75. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 76. AstraZeneca Major Business
Table 77. AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 78. AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. AstraZeneca Recent Developments/Updates
Table 80. AstraZeneca Competitive Strengths & Weaknesses
Table 81. Novartis Basic Information, Manufacturing Base and Competitors
Table 82. Novartis Major Business
Table 83. Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 84. Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Novartis Recent Developments/Updates
Table 86. Novartis Competitive Strengths & Weaknesses
Table 87. Apellis Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 88. Apellis Pharmaceuticals Major Business
Table 89. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 90. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Apellis Pharmaceuticals Recent Developments/Updates
Table 92. Apellis Pharmaceuticals Competitive Strengths & Weaknesses
Table 93. Roche Basic Information, Manufacturing Base and Competitors
Table 94. Roche Major Business
Table 95. Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 96. Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Roche Recent Developments/Updates
Table 98. Roche Competitive Strengths & Weaknesses
Table 99. Amgen Basic Information, Manufacturing Base and Competitors
Table 100. Amgen Major Business
Table 101. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 102. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Amgen Recent Developments/Updates
Table 104. Amgen Competitive Strengths & Weaknesses
Table 105. Chugai Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 106. Chugai Pharmaceutical Major Business
Table 107. Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 108. Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Chugai Pharmaceutical Recent Developments/Updates
Table 110. Chugai Pharmaceutical Competitive Strengths & Weaknesses
Table 111. Sobi Basic Information, Manufacturing Base and Competitors
Table 112. Sobi Major Business
Table 113. Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 114. Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Sobi Recent Developments/Updates
Table 116. Sobi Competitive Strengths & Weaknesses
Table 117. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 118. Samsung Bioepis Major Business
Table 119. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 120. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Samsung Bioepis Recent Developments/Updates
Table 122. Samsung Bioepis Competitive Strengths & Weaknesses
Table 123. Teva Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 124. Teva Pharmaceutical Industries Major Business
Table 125. Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 126. Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Teva Pharmaceutical Industries Recent Developments/Updates
Table 128. Teva Pharmaceutical Industries Competitive Strengths & Weaknesses
Table 129. CANbridge Pharmaceuticals Inc. Basic Information, Manufacturing Base and Competitors
Table 130. CANbridge Pharmaceuticals Inc. Major Business
Table 131. CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 132. CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. CANbridge Pharmaceuticals Inc. Recent Developments/Updates
Table 134. CANbridge Pharmaceuticals Inc. Competitive Strengths & Weaknesses
Table 135. Kira Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 136. Kira Pharmaceuticals Major Business
Table 137. Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 138. Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Kira Pharmaceuticals Recent Developments/Updates
Table 140. Kira Pharmaceuticals Competitive Strengths & Weaknesses
Table 141. Wuhan Createrna Science and Technology Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 142. Wuhan Createrna Science and Technology Co., Ltd. Major Business
Table 143. Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 144. Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Wuhan Createrna Science and Technology Co., Ltd. Recent Developments/Updates
Table 146. Wuhan Createrna Science and Technology Co., Ltd. Competitive Strengths & Weaknesses
Table 147. NovelMed Basic Information, Manufacturing Base and Competitors
Table 148. NovelMed Major Business
Table 149. NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 150. NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. NovelMed Recent Developments/Updates
Table 152. NovelMed Competitive Strengths & Weaknesses
Table 153. Akari Therapeutics Basic Information, Manufacturing Base and Competitors
Table 154. Akari Therapeutics Major Business
Table 155. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 156. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Akari Therapeutics Recent Developments/Updates
Table 158. Akari Therapeutics Competitive Strengths & Weaknesses
Table 159. Omeros Corporation Basic Information, Manufacturing Base and Competitors
Table 160. Omeros Corporation Major Business
Table 161. Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 162. Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 163. Omeros Corporation Recent Developments/Updates
Table 164. Omeros Corporation Competitive Strengths & Weaknesses
Table 165. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 166. Regeneron Pharmaceuticals Major Business
Table 167. Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product and Services
Table 168. Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 169. Regeneron Pharmaceuticals Recent Developments/Updates
Table 170. Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
Table 171. Global Key Players of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Upstream (Raw Materials)
Table 172. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Typical Customers
Table 173. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Typical Distributors
LIST OF FIGURES
Figure 1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Picture
Figure 2. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032) & (K Doses)
Figure 5. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price (2021-2032) & (US$/Dose)
Figure 6. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Region (2021-2032)
Figure 7. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share by Region (2021-2032)
Figure 8. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032) & (K Doses)
Figure 9. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032) & (K Doses)
Figure 10. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032) & (K Doses)
Figure 11. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032) & (K Doses)
Figure 12. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 15. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Market Share by Region (2021-2032)
Figure 16. United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 17. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 18. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 19. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 20. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 21. ASEAN Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 22. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 23. Producer Shipments of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Markets in 2025
Figure 26. United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share 2025
Figure 30. China Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share 2025
Figure 32. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Type in 2025
Figure 34. Oral Drugs
Figure 35. Injectable Drugs
Figure 36. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share by Type (2021-2032)
Figure 37. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Type (2021-2032)
Figure 38. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Type (2021-2032) & (US$/Dose)
Figure 39. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Complement Target, (USD Million), 2021 & 2025 & 2032
Figure 40. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Complement Target in 2025
Figure 41. C5 Inhibitors
Figure 42. C3 Inhibitors
Figure 43. Other
Figure 44. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share by Complement Target (2021-2032)
Figure 45. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Complement Target (2021-2032)
Figure 46. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Complement Target (2021-2032) & (US$/Dose)
Figure 47. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Duration of Action, (USD Million), 2021 & 2025 & 2032
Figure 48. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Duration of Action in 2025
Figure 49. Short-Acting: < 2 Weeks
Figure 50. Medium-Acting: 2?8 Weeks
Figure 51. Long-Acting: > 8 Weeks
Figure 52. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share by Duration of Action (2021-2032)
Figure 53. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Duration of Action (2021-2032)
Figure 54. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Duration of Action (2021-2032) & (US$/Dose)
Figure 55. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 56. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Application in 2025
Figure 57. Pharmaceutical and Biotechnology Companies
Figure 58. Clinical
Figure 59. Others
Figure 60. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share by Application (2021-2032)
Figure 61. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Application (2021-2032)
Figure 62. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Application (2021-2032) & (US$/Dose)
Figure 63. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Chain
Figure 64. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Procurement Model
Figure 65. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Model
Figure 66. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Channels, Direct Sales, and Distribution
Figure 67. Methodology
Figure 68. Research Process and Data Source
Figure 1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Picture
Figure 2. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032) & (K Doses)
Figure 5. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price (2021-2032) & (US$/Dose)
Figure 6. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Region (2021-2032)
Figure 7. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share by Region (2021-2032)
Figure 8. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032) & (K Doses)
Figure 9. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032) & (K Doses)
Figure 10. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032) & (K Doses)
Figure 11. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production (2021-2032) & (K Doses)
Figure 12. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 15. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Market Share by Region (2021-2032)
Figure 16. United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 17. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 18. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 19. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 20. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 21. ASEAN Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 22. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption (2021-2032) & (K Doses)
Figure 23. Producer Shipments of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Markets in 2025
Figure 26. United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share 2025
Figure 30. China Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share 2025
Figure 32. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Type in 2025
Figure 34. Oral Drugs
Figure 35. Injectable Drugs
Figure 36. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share by Type (2021-2032)
Figure 37. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Type (2021-2032)
Figure 38. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Type (2021-2032) & (US$/Dose)
Figure 39. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Complement Target, (USD Million), 2021 & 2025 & 2032
Figure 40. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Complement Target in 2025
Figure 41. C5 Inhibitors
Figure 42. C3 Inhibitors
Figure 43. Other
Figure 44. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share by Complement Target (2021-2032)
Figure 45. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Complement Target (2021-2032)
Figure 46. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Complement Target (2021-2032) & (US$/Dose)
Figure 47. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Duration of Action, (USD Million), 2021 & 2025 & 2032
Figure 48. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Duration of Action in 2025
Figure 49. Short-Acting: < 2 Weeks
Figure 50. Medium-Acting: 2?8 Weeks
Figure 51. Long-Acting: > 8 Weeks
Figure 52. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share by Duration of Action (2021-2032)
Figure 53. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Duration of Action (2021-2032)
Figure 54. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Duration of Action (2021-2032) & (US$/Dose)
Figure 55. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 56. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Application in 2025
Figure 57. Pharmaceutical and Biotechnology Companies
Figure 58. Clinical
Figure 59. Others
Figure 60. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Market Share by Application (2021-2032)
Figure 61. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Value Market Share by Application (2021-2032)
Figure 62. World Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Application (2021-2032) & (US$/Dose)
Figure 63. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Chain
Figure 64. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Procurement Model
Figure 65. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Model
Figure 66. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Channels, Direct Sales, and Distribution
Figure 67. Methodology
Figure 68. Research Process and Data Source
